CA2465565A1 - Compositions pharmaceutiques d'atorvastatine - Google Patents

Compositions pharmaceutiques d'atorvastatine Download PDF

Info

Publication number
CA2465565A1
CA2465565A1 CA002465565A CA2465565A CA2465565A1 CA 2465565 A1 CA2465565 A1 CA 2465565A1 CA 002465565 A CA002465565 A CA 002465565A CA 2465565 A CA2465565 A CA 2465565A CA 2465565 A1 CA2465565 A1 CA 2465565A1
Authority
CA
Canada
Prior art keywords
atorvastatin
wet
composition
optionally
granules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002465565A
Other languages
English (en)
Inventor
Kenneth Craig Waterman
Michael Bruce Fergione
Barbara Alice Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CA2465565A1 publication Critical patent/CA2465565A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
CA002465565A 2003-06-12 2004-04-29 Compositions pharmaceutiques d'atorvastatine Abandoned CA2465565A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47811903P 2003-06-12 2003-06-12
US60/478,119 2003-06-12

Publications (1)

Publication Number Publication Date
CA2465565A1 true CA2465565A1 (fr) 2004-12-12

Family

ID=33551806

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002465565A Abandoned CA2465565A1 (fr) 2003-06-12 2004-04-29 Compositions pharmaceutiques d'atorvastatine

Country Status (15)

Country Link
EP (1) EP1635814A1 (fr)
JP (1) JP2006527260A (fr)
KR (1) KR100814218B1 (fr)
CN (1) CN100434069C (fr)
AR (1) AR044774A1 (fr)
AU (1) AU2004246868B2 (fr)
BR (1) BRPI0411344A (fr)
CA (1) CA2465565A1 (fr)
CO (1) CO5650230A2 (fr)
MX (1) MXPA05013281A (fr)
NO (1) NO20060022L (fr)
NZ (1) NZ543337A (fr)
RU (1) RU2332211C2 (fr)
TW (1) TW200503690A (fr)
WO (1) WO2004110431A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40667E1 (en) 1989-07-21 2009-03-17 Warner-Lambert Company Llc [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
WO2009000286A1 (fr) * 2007-06-25 2008-12-31 Parmatheen S.A. Formulation pharmaceutique améliorée contenant un inhibiteur de la hmg-coa réductase et son procédé de préparation
KR20100125346A (ko) * 2008-02-27 2010-11-30 토멘 메디칼 아게 임플란트 및 이의 제조 방법
AU2009292615B2 (en) * 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
RU2404767C1 (ru) * 2009-08-11 2010-11-27 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма, обладающая гиполипидемической и гипохолестеринемической активностью, и способ ее получения
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
RU2014124118A (ru) 2011-11-15 2015-12-27 Др. Редди'С Лабораторис Лтд. Фармацевтические препараты, включающие аторвастатин и глимепирид
LT3470063T (lt) * 2012-11-02 2025-02-10 Vertex Pharmaceuticals Incorporated Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
CN104069078B (zh) * 2014-05-22 2019-06-11 西藏九瑞健康股份有限公司 阿托伐他汀钙药物组合物及其制备方法
CA2954840A1 (fr) * 2014-07-25 2016-01-28 Novartis Ag Formulation de comprime de 2-fluoro-n-methyl-4-[7-(quinoline -6-ylmethyl) imidazo[1,2-b] [1,2,4]triazine -2-yl]benzamide
KR101658350B1 (ko) * 2015-02-06 2016-09-30 경성대학교 산학협력단 고지혈증 치료에 유용한 약학 조성물
WO2016145132A1 (fr) * 2015-03-12 2016-09-15 Fmc Corporation Dispersions solides
JPWO2017170858A1 (ja) 2016-03-31 2019-02-14 インターセプト ファーマシューティカルズ， インコーポレイテッド 溶出性に優れた経口製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3254219B2 (ja) * 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
JPH06242003A (ja) * 1993-02-12 1994-09-02 Nkk Corp 鉄鋼中のアルミナの粒度測定方法
JP3014040B2 (ja) * 1996-10-30 2000-02-28 信久 川野 食物繊維パン及びその製造法
CA2406574C (fr) * 2000-04-10 2006-12-05 Teva Pharmaceutical Industries, Ltd. Compositions pharmaceutiques stables contenant des acides 7-substitues-3,5-dihydroxyheptanoiques ou acides 7-substitues-3,5-dihydroxyheptenoiques
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
EP1226818A1 (fr) * 2001-01-26 2002-07-31 Pfizer Products Inc. Formulation pharmaceutique présentant des propriétés de cohesion et de compressibilité améliorées
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
EP1291017A3 (fr) * 2001-09-10 2003-07-02 Warner-Lambert Company Utilisation de statines pour prévenir la formation d'osteoclastes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40667E1 (en) 1989-07-21 2009-03-17 Warner-Lambert Company Llc [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof

Also Published As

Publication number Publication date
CN100434069C (zh) 2008-11-19
CO5650230A2 (es) 2006-06-30
BRPI0411344A (pt) 2006-07-11
AR044774A1 (es) 2005-10-05
RU2332211C2 (ru) 2008-08-27
NZ543337A (en) 2008-03-28
TW200503690A (en) 2005-02-01
KR100814218B1 (ko) 2008-03-17
CN1805741A (zh) 2006-07-19
NO20060022L (no) 2006-01-03
WO2004110431A1 (fr) 2004-12-23
AU2004246868B2 (en) 2008-01-17
MXPA05013281A (es) 2006-03-09
RU2005136745A (ru) 2006-07-27
JP2006527260A (ja) 2006-11-30
KR20060020666A (ko) 2006-03-06
AU2004246868A1 (en) 2004-12-23
EP1635814A1 (fr) 2006-03-22

Similar Documents

Publication Publication Date Title
US7790197B2 (en) Pharmaceutical compositions of atorvastatin
US20090226510A1 (en) Pharmaceutical compositions of atorvastatin
CN1630510B (zh) 药物形式的阿托伐他汀钙、其组合物和包含阿托伐他汀钙的药物制剂
US20090196932A1 (en) Pharmaceutical compositions of atorvastatin
AU2004246868B2 (en) Stable compositions of atorvastatin prepared with wet granulation
KR100760112B1 (ko) 아토르바스타틴의 제약 조성물
KR101171375B1 (ko) 난용성 약물을 함유하는 경구 제형
WO2006059224A1 (fr) Compositions pharmaceutiques d'atorvastatine amorphe et leur procede de preparation
AU2008200759A1 (en) Stable compositions of atorvastatin prepared with wet granulation
HK1089369A (en) Stable compositions of atorvastatin prepared with wet granulation
HK1088231A (en) Pharmaceutical compositions comprising atorvastatin manufactured without granulation
HK1089370A (en) Pharmaceutical compositions of atorvastatin

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued